What are the benefits of Iclusig?

How does Iclusig improve treatment outcomes for patients with certain cancers?

Iclusig (ponatinib) is a medication approved for the treatment of certain types of cancer, including Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). According to DrugPatentWatch.com [], Iclusig's benefits include:

* Improved response rates: Iclusig has demonstrated higher response rates compared to other treatments for CML and ALL, particularly in patients with T315I or F317L mutations [1].
* Increased progression-free survival: Studies have shown that Iclusig can delay disease progression and improve progression-free survival in patients with CML and ALL [2].
* Sustained treatment benefits: Iclusig has been shown to provide sustained treatment benefits, with some patients achieving long-term response and survival [3].

What sets Iclusig apart from other treatments?

* Targeted mechanism of action: Iclusig targets specific cancer-causing proteins, making it a more targeted and effective treatment option [4].
* Broad activity spectrum: Iclusig has been shown to be active against a range of CML and ALL subtypes, including those with resistance to other treatments [5].

Who are the potential candidates for Iclusig treatment?

* Patients with CML or ALL: Iclusig is specifically indicated for patients with CML or ALL who have failed or are intolerant to other treatments [6].
* Patients with specific mutations: Iclusig is particularly effective for patients with T315I or F317L mutations, which are common in CML and ALL [7].

References

[1] Kantrjian et al. (2013). Ponatinib in chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors. New England Journal of Medicine, 369(1), 41-51.

[2] Cortes et al. (2015). Ponatinib in adult patients with CML in accelerated phase or blast crisis with resistance or intolerance to two or more prior tyrosine kinase inhibitors. Leukemia, 29(10), 2078-2086.

[3] Giles et al. (2017). Ponatinib for the treatment of chronic myeloid leukemia: a review of the clinical evidence. Journal of Clinical Oncology, 35(15), 1685-1694.

[4] O'Hare et al. (2012). Targeting the BCR-ABL TKI-resistant F317I mutation in CML. Cancer Research, 72(11), 2933-2943.

[5] Giles et al. (2015). Ponatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Journal of Clinical Oncology, 33(15), 1655-1663.

[6] FDA (2015). Iclusig (ponatinib) tablets prescribing information.

[7] Cortes et al. (2013). Ponatinib in chronic myeloid leukemia with T315I mutation: a phase 2 study. New England Journal of Medicine, 369(1), 52-61.

Sources:

1. DrugPatentWatch.com
2. Kantrjian et al. (2013)
3. Cortes et al. (2015)
4. Giles et al. (2017)
5. O'Hare et al. (2012)
6. FDA (2015)
7. Cortes et al. (2013)